Pluri (NASDAQ:PLUR – Get Rating) and Vir Biotechnology (NASDAQ:VIR – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Profitability This table compares Pluri and Vir Biotechnology’s net margins, return […]
RSV causes little illness in most healthy adults, but those with underlying conditions are at risk. This first vaccine is designed for adults 60 and older, but other RSV vaccines and drugs are in the works, including a vaccine to protect infants.
Malaria is a leading killer in Africa and other developing countries, claiming more than 1 million lives each year, most of them children. A small clinical trial conducted by an international team of researchers in Mali has found that a candidate malaria vaccine was safe and elicited strong immune responses in the 40 Malian adults who received it.